Axiogenesis AG at a glance

Axiogenesis AG is a pioneer of murine embryonic stem cell technology and the world leader in murine stem cell-derived products. Its proprietary production technology enables the commercialization of pure stem cell-derived cardiomyocytes (Cor.At^®), smooth muscle cells (Smac.4M^®) and endothelial cells (Endo.4M^®) of outstanding product quality (preparation purity, freeze-thaw stability, lot-to-lot uniformity). 

Axiogenesis AG offers a unique service portfolio, from which Cor.At cardiomyocytes evolved as the gold standard tool for in vitro cardiac toxicology and drug discovery. It provides assays for experiments in electrophysiology, toxicology, cytotoxity, embryotoxicity and a uniquein vitro disease model for cardiac hypertrophy.

Currently, Axiogenesis is expanding its portfolio through the induced pluripotent stem cell (iPS) technology by introducing murine IPS based products and services in addition to the ES based product family. The service Cor.4U-MEA^® introduces human cardiomyocytes obtained from iPS cells on multi-electrode arrays for cardiac safety pharmacology testing, to be followed by additional products and service lines .

CM-Clinical Modeling^® is Axiogenesis’ screening platform concept currently under development to support in-house drug discovery. Stem cell-derived tissues (heart, liver, neuron etc.) modulate specific pathological scenarios highly relevant for identification and stratification of new active pharmaceutical ingredients. Axiogenesis’ proprietary hypertrophy platform will fill pharma pipelines for future cardiomyopathy therapy.